Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depres... Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine sublingual formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer’s disease; BMND06 is in Phase I clinical trial for treatment of morbid obesity; and BMDO9 is in Phase I clinical trial for treatment of Parkinson’s disease. It is also developing preclinical drug candidates, including BMND02 for the treatment of fibromyalgia; BMND03 for the treatment of addictive disorders; BMND05 to treat chronic pain; and BMND07 for the treatment of major depressive disorder. The company is headquartered in Vancouver, Canada. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.0111 | 0.0111 | 0.0111 | 300 | 0.0111 | CS |
| 4 | 0 | 0 | 0.0111 | 0.0111 | 0.0111 | 300 | 0.0111 | CS |
| 12 | -0.1194 | -91.4942528736 | 0.1305 | 0.1305 | 0.0111 | 1314 | 0.11064986 | CS |
| 26 | -0.1029 | -90.2631578947 | 0.114 | 0.1305 | 0.011 | 1520 | 0.07055597 | CS |
| 52 | -0.0889 | -88.9 | 0.1 | 0.1305 | 0.011 | 1188 | 0.07732451 | CS |
| 156 | -0.0889 | -88.9 | 0.1 | 0.7 | 0.011 | 2695 | 0.25378296 | CS |
| 260 | -0.7679 | -98.5750962773 | 0.779 | 1.63 | 0.011 | 2196 | 0.27496694 | CS |
Implanting
5分前
HenryB3
7分前
RRP60
13分前
WhiteOwl
14分前
Jack_Bolander
20分前
jammy32
21分前
TaxHadas
22分前
erg61
26分前
LOB
27分前
bobby1151
30分前
mick
30分前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。